Cyclin D1 suppresses retinoblastoma protein-mediated inhibition of TAFII250 kinase activity

J L Siegert1, J J Rushton, W R Sellers

  • 1Department of Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine, Pennsylvania 15261, USA.

Oncogene
|December 29, 2000
PubMed

Insights

Cyclin D1 blocks retinoblastoma protein (Rb) inhibition of TAFII250 kinase activity. This suggests cyclin D1 independently regulates Rb activity by interacting with TAFII250, not Rb.

Area of Science:

  • Molecular Biology
  • Cell Cycle Regulation
  • Tumor Suppressor Proteins

Background:

  • Retinoblastoma protein (Rb) inhibits TAFII250 kinase activity.
  • Cyclin D1 binds to TAFII250 near the Rb-binding site.

Purpose of the Study:

  • Investigate if cyclin D1 affects the Rb-TAFII250 interaction.
  • Determine the mechanism by which cyclin D1 influences TAFII250 kinase activity.

Main Methods:

  • In vitro kinase assays.
  • Coincubation of Rb, cyclin D1, and TAFII250.
  • Use of Rb mutants and adenovirus E1A protein.

Main Results:

  • Cyclin D1 blocks Rb-mediated inhibition of TAFII250 kinase activity.
  • Cyclin D1 does not affect TAFII250 kinase activity alone.
  • p107 inhibition of TAFII250 is also alleviated by cyclin D1.
  • Cyclin D1 acts via TAFII250, not Rb, and does not compete with Rb for binding.
  • Adenovirus E1A protein mimics cyclin D1's effect.

Conclusions:

  • Cyclin D1 regulates Rb activity through TAFII250.
  • Cyclin D1 may independently modulate Rb function.
  • This interaction offers a novel regulatory mechanism for Rb activity.

Related Concept Videos

Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...